Wedbush Downgrades bluebird bio (BLUE) to Neutral, Following Clinical Update

February 16, 2021 12:46 PM EST
Get Alerts BLUE Hot Sheet
Price: $25.98 -3.71%

Rating Summary:
    14 Buy, 15 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 12 | New: 23
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten downgraded bluebird bio (NASDAQ: BLUE) from Outperform to Neutral with a price target of $29.00 (from $73.00).

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $45.76 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories